Our results reinforce previous studies that AR-targeted therapy maybe insufficient to achieve long term PCa responses in some patients [8] and show that co-targeting the AR axis and fat oxidation may provide additional anti-cancer benefit. The gene discussed is AR; the disease is cancer.